Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Rhea-AI Summary
Plus Therapeutics (Nasdaq: PSTV), through its wholly owned subsidiary CNSide Diagnostics, signed a regional coverage agreement with Medical Mutual effective July 1, 2026. The agreement covers approximately 1.2 million people across Ohio and Kentucky for the CNSide® cerebrospinal fluid Tumor Cell Enumeration assay, increasing total contracted coverage to about 127 million people.
The CNSide® CSF Assay Platform is used for rapid diagnosis, treatment monitoring, and guidance in leptomeningeal metastases. According to Plus Therapeutics, more than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions since 2020, with reported sensitivity of 92%, specificity of 95%, and influence on treatment decisions in 90% of cases.
Positive
- Medical Mutual agreement adds coverage for ~1.2 million people in Ohio and Kentucky effective July 1, 2026
- CNSide CSF TCE assay now has contracted coverage for approximately 127 million people
- More than 11,000 CNSide tests performed at over 120 U.S. cancer institutions since 2020
- Reported high diagnostic performance with 92% sensitivity and 95% specificity
- CNSide assay reported to influence treatment decisions in 90% of cases
Negative
- None.
News Market Reaction – PSTV
On the day this news was published, PSTV gained 2.35%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.3% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $645K to the company's valuation, bringing the market cap to $28.09M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 16 | CNSide partnership | Positive | -4.4% | Collaboration added next-generation sequencing capabilities to the CNSide CSF assay platform. |
| Jul 14 | Guidelines update | Positive | +5.5% | Guidelines update reinforced CSF analysis and CNSide’s monitoring positioning. |
| Jun 30 | Business update | Positive | +1.9% | Mid-year update affirmed milestones and detailed rebranding and development progress. |
| Jun 25 | National coverage agreement | Positive | +7.6% | National Elevance agreement added 45.4 million covered people to CNSide. |
| Jun 23 | Business update scheduling | Neutral | +2.5% | Company scheduled a business update covering CNSide, Reyobiq, and strategy. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Payer-coverage news produced a positive prior reaction, while a subsequent CNSide partnership declined, indicating mixed responses across related announcements.
Key Terms
cerebrospinal fluid medical
tumor cell enumeration medical
leptomeningeal metastases medical
specificity medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a regional agreement with Medical Mutual effective July 1, 2026, covering approximately 1.2 million people throughout Ohio and Kentucky, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This brings CNSide CSF TCE assay total contracted coverage to approximately 127 million people.
The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utility of CNSide® over standard of care has been shown in 11 peer-reviewed publications, the FORESEE clinical trial, and has been validated in the market through real-world use.
More than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions since 2020, delivering high sensitivity (
This test is available exclusively through CNSide Diagnostics, LLC. as a testing service provided to health care professionals in the U.S.
About CNSide Diagnostics, LLC
CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc., develops and commercializes proprietary laboratory-developed tests such as CNSide®, which is designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis of cerebrospinal fluid to inform and improve the management of patients with leptomeningeal metastases. For more information, please visit www.cnside-dx.com.
About Plus Therapeutics
Plus Therapeutics, Inc. (NASDAQ: PSTV) is a clinical-stage healthcare company advancing an integrated approach to central nervous system (“CNS”) cancers through precision therapeutics, molecular diagnostics and data-driven technologies. The Company's lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being developed for the treatment of leptomeningeal metastases, recurrent glioblastoma and pediatric brain cancers. Its CNSide® cerebrospinal fluid assay platform is designed to provide diagnostic and disease monitoring information to support the management of patients with CNS cancers. Together with its growing data and artificial intelligence capabilities, Plus Therapeutics is building an integrated CNS oncology platform intended to improve clinical decision-making, accelerate therapeutic development and advance personalized care for patients with CNS cancers.
Effective August 3, 2026, Plus Therapeutics will change its corporate name to Cerenome, Inc. and begin trading under the Nasdaq ticker symbol CNSY. Until that date, the Company will continue to operate as Plus Therapeutics and trade under the ticker symbol PSTV.
For more information, please visit www.plustherapeutics.com. Beginning August 3, 2026, additional information will be available at www.cerenome.com.
About Medical Mutual
Founded in 1934, Medical Mutual is the oldest and one of the largest health insurance companies based in Ohio. We provide peace of mind to more than 1.2 million members through our high-quality health, life, disability, dental, vision and indemnity plans. We offer fully insured and self-funded group coverage, including stop loss, as well as Medicare Advantage, Medicare Supplement, and individual plans. For more information, please visit http://www.medicalmutual.com/.
Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.
Investor Contact
CORE IR
investor@plustherapeutics.com
